Home Biosimilar Antibodies Others Others Citatuzumab (Anti-EpCAM / TROP1 / CD326)
For research use only. Not for use in humans.

Citatuzumab (Anti-EpCAM / TROP1 / CD326)

Synonyms: VB6-845

Citatuzumab (Anti-EpCAM / TROP1 / CD326) is a recombinant immunotoxin that composed of humanized monoclonal antibody targeting EpCAM. It has antitumor activity and can be used in treatment of cancer. MW :145.4 KD.

Citatuzumab (Anti-EpCAM / TROP1 / CD326)

Quality Control

Batch: A265101 Purity: 99% Protein concentration: 5.537mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Citatuzumab (Anti-EpCAM / TROP1 / CD326) is a recombinant immunotoxin that composed of humanized monoclonal antibody targeting EpCAM. It has antitumor activity and can be used in treatment of cancer. MW :145.4 KD.
References

Product Details

CAS No. 945228-49-9
Molecular Weight 145.4
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06093698 NOT_YET_RECRUITING Recurrent or Metastatic Solid Tumors ITabMed Co., Ltd. 2023-12-01 PHASE1
NCT04819399 UNKNOWN Drug: Catumaxomab Urinary Bladder Neoplasms Lindis Biotech GmbH 2020-07-07 PHASE1
NCT04501744 COMPLETED Drug: Cohort 1 of M701|Drug: Cohort 2 of M701|Drug: Cohort 3 Malignant Ascites; Cancer Wuhan YZY Biopharma Co., Ltd. 2018-09-30 PHASE1
NCT01504256 COMPLETED Drug: catumaxomab, Fluorouracil, leucovorin, oxaliplatin, do Gastric Adenocarcinoma With Peritoneal Carcinomatosis; Siewert Type II Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis; Siewert Type III Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis AIO-Studien-gGmbH 2011-10 PHASE2
NCT00326885 COMPLETED Drug: catumaxomab Malignant Ascites Neovii Biotech 2006-06 PHASE2
NCT00464893 COMPLETED Drug: Catumaxomab|Drug: catumaxomab Gastric Cancer; Gastric Adenocarcinoma Neovii Biotech 2007-04 PHASE2

(data from https://clinicaltrials.gov, updated on 2023-10-23)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.